A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy
Phase of Trial: Phase II
Latest Information Update: 20 May 2015
At a glance
- Drugs DA 9801 (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- Sponsors Dong-A ST
- 18 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 30 Sep 2014 Planned End Date changed from 1 Sep 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.
- 30 Sep 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.